Narayana Hrudayalaya Q2FY25: Revenue jumps 7.3%; PAT drops 12.3%

Narayana Hrudayalaya announced its financial results for the second quarter of the financial year 2025.

Consolidated operating revenue jumped 7.3 percent to ₹ 14,000 million in Q2 FY25 as compared to ₹13,052 million in Q2FY24

Consolidated EBITDA increased 1.7% YoY to ₹ 3,320 million in Q2FY25 % as against ₹ 3,265 million in Q2 FY24.

Consolidated PAT dropped 12.3% to ₹ 1,988 million as compared to ₹ 2,267 million in Q2 FY24.

India operating revenue was ₹ 11,684 million in Q2 FY25 as compared to ₹ 10,527 million in the corresponding period of the previous year, reflecting a growth of +11.0% YoY and +7.6% QoQ.

Cayman operating revenue was ₹ 2,423 million in for Q2 FY25 as compared to ₹ 2,607 million in the corresponding period of the previous year, reflecting a drop of 7.0% YoY and -9.4% QoQ.

“The second quarter of the fiscal year has delivered strong performance after a robust start to the year. We are pleased to report the highest-ever revenue on a quarterly basis with sustainable profitability margins, which is on account of improvement in realizations and increased domestic patient footfalls. Despite the slowdown in international patient inflows due to geopolitical tensions in the neighborhood, we have been able to show overall growth in revenues during the quarter through our enhanced focus on domestic business. The performance improvement is seen across our flagship units, and other hospitals, and steady improvements in the performance of our newer hospitals. There is a decline in the HCCI revenue and margins for the quarter on account of the steps we have undertaken to optimize the operations between the existing and the new hospitals, and the costs in the new hospital being incurred upfront, which we believe are transitory and should normalize over the next few quarters. NHIC has delivered another strong quarter of increased patient transactions and revenue growth. We remain on track to deliver on our expectations for the full fiscal year for all our businesses including the new ventures,” said Dr. Emmanuel Rupert, MD and Group CEO.
MB Bureau